

RARE EQUITY PRIVATE LIMITED

151, 15th Floor, Nariman Bhavan, Nariman Point, Mumbai-400021

CIN: U74110MH1993PTC074456 | www.rareequity.net | Contact No: 022 4004 8766/022 6659 0100 | rareequity@rareenterprises.net

August 14, 2024

BSE Limited

Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai – 400 001.

Scrip Code: 973302 & 973303

Subject: Intimation under Regulation 52(7) and 52(7A) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 for the quarter ended June 30, 2024.

Dear Sir/ Madam,

Pursuant to Regulation 52(7) of SEBI (Listing Obligation and Disclosure Requirements) Regulation 2015, I hereby confirm and disclose that the funds of Rs. 500 Crores (Rupees Five Hundred Crores only) raised by issue of Non-Convertible Debentures were utilized by the Company for buying the shares of Zenex Animal Health India Private Limited for which the proceeds were raised.

Further, pursuant to Regulation 52(7A) of SEBI (Listing Obligation and Disclosure Requirements) Regulation 2015, I hereby confirm that, there is no material deviation, in the use of the issue proceeds, from the object of the issue, for which the proceeds were raised.

Kindly take the same on record.

For Rare Equity Private Limited,

Vrushali Deshpande
Executive Director
DIN: 05216743